# TiNivo-2 (NCT04987203)

> Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04987203
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AVEO Pharmaceuticals, Inc.
- Conditions: Renal Cell Carcinoma
- Interventions: Tivozanib; Nivolumab
- Enrollment: 343
- Primary outcome: Progression free survival

## Questions raised in the commentary

_Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice._

The commentary discusses TiNivo-2’s comparison of tivozanib plus nivolumab with tivozanib alone after prior immune-checkpoint inhibitor therapy, including trial design and treatment sequencing in metastatic renal cell carcinoma. Discussion covers whether the trial clarifies a possible distinction between PD-1 and PD-L1 rechallenge raised in relation to CONTACT-03, and the broader role of checkpoint blockade after progression. Speakers also discuss tivozanib dosing, side-effect profile, patient-reported outcomes, and whether further research on pembrolizumab rechallenge is warranted.

## Indexed commentary on TiNivo-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 102
- YouTube: 62
- Podcasts: 30
- X videos: 3
- Bluesky threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=tinivo-2-nct04987203

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04987203", "email": "<work email>"}; the inbox owner confirms by the emailed link.